

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5445299

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
DS PHARMA BIOMEDICAL CO., LTD.	11/29/2018
RECEIVING PARTY DATA	
Name:	SUMITOMO CHEMICAL COMPANY, LIMITED
Street Address:	27-1, SHINKAWA 2-CHOME, CHUO-KU
City:	TOKYO
State/Country:	JAPAN
Postal Code:	104-8260
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	15645636
Patent Number:	8137966
Patent Number:	8628957
Patent Number:	9700023
CORRESPONDENCE DATA	
Fax Number:	(312)616-5700
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(312) 616-5600
Email:	mgreer@leydig.com
Correspondent Name:	JOHN KILYK, JR.
Address Line 1:	LEYDIG, VOIT & MAYER, LTD.
Address Line 2:	TWO PRUDENTIAL PLAZA, SUITE 4900
Address Line 4:	CHICAGO, ILLINOIS 60601-6731
ATTORNEY DOCKET NUMBER:	DS PHARMA TO SUMITOMO
NAME OF SUBMITTER:	JOHN KILYK, JR.
SIGNATURE:	/John Kilyk, Jr./
DATE SIGNED:	03/28/2019
Total Attachments: 2	
source=Assignment-DSPharmatoSumitomoChemical#page1.tif	
source=Assignment-DSPharmatoSumitomoChemical#page2.tif	

ASSIGNMENT

WHEREAS, DS Pharma Biomedical Co., Ltd., 33-94, Enoki-cho, Suita-shi, Osaka 564-0053 Japan, hereinafter referred to as Assignor, is an owner of certain inventions and the following U.S. patent application and U.S. patents directed thereto:

1. U.S. Patent No. 8,137,966, issued March 20, 2012,
2. U.S. Patent No. 8,628,957, issued January 14, 2014,
3. U.S. Patent No. 9,700,023, issued July 11, 2017, and
4. U.S. Patent Application No. 15/645,636, filed July 10, 2017.

WHEREAS, SUMITOMO CHEMICAL COMPANY, LIMITED, 27-1, Shinkawa 2-chome, Chuo-ku, Tokyo 104-8260 Japan, hereinafter referred to as Assignee, is desirous of acquiring the entire U.S. right, title, and interest of Assignor in, to, and under the aforesaid inventions and the entire right, title, and interest of Assignor in, to and under the aforesaid U.S. patent application and U.S. patents, including the entire priority right derived therefrom,

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Assignor assigns and transfers to Assignee the entire U.S. right, title, and interest of Assignor in, to, and under the aforesaid inventions and the entire right, title, and interest of Assignor in, to, and under the aforesaid U.S. patent application and U.S. patents, and any other such U.S. patent applications (e.g., continuations, continuations-in-part, divisionals, reissues, and reexaminations) that may be filed in the U.S. on the inventions and/or with a claim of priority to the referenced U.S. patent application and U.S. patents, as well as U.S. patents that may issue thereon and that may be modified as the result of applicable procedures (e.g., supplemental examinations, ex parte reexaminations, inter partes reexaminations, inter partes reviews, and post-grant reviews),

Assignor conveys to the Assignee the right to make applications in Assignee's own behalf for protection of the aforesaid inventions in the U.S. and to claim priority in the U.S. to the aforementioned U.S. patent application and U.S. patents and any priority documents referenced therein under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue the U.S. patent application and U.S. patents identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. on the aforesaid inventions, and in enforcing any rights accruing as a result of such U.S. patent application and U.S. patents, by, for example, executing statements and other affidavits,

Assignment

Assignor and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor and Assignee agree that U.S. law governs this assignment, and

Assignee acknowledges and accepts this assignment.

IN WITNESS WHEREOF, Assignor has caused one of its duly authorized officers to hereunder set his/her hand on the date shown below.

Date November 29, 2018

Susumu Nakajima
Name: Susumu NAKAJIMA
Title: Representative Director, President
Authorized Officer of Assignor
DS Pharma Biomedical Co., Ltd.

=====